Enrollment and	Preterm and term healthy infants Consented (N=200); Enrolled (N=200)			
Allocation	<b>▼</b>		<del></del>	
	Preterm infants (n=100)			Term infants (n=100)
Infant series	GA <29 weeks (n=25) Received PCV13 (n=25)	GA 29 to <32 weeks (n=50) Received PCV13 (n=50)	GA 32 to <37 weeks (n=25) Received PCV13 (n=25)	GA≥37 weeks (n=100) Received PCV13 (n=100)
Infant series analysis	Included in EIP (n= 25) No subject excluded from EIP	Included in EIP (n= 50) No subject excluded from EIP	Included in EIP (n= 24) Excluded from EIP (n=1) •No assay result (n=1)	Included in EIP (n=98) Excluded from EIP (n=2) •No assay result (n=1) •After infants series blood drawout of
	<u> </u>	<u> </u>		window (n=1)
Toddler dose	Received PCV13 (n=24)	Received PCV13 (n=50)	Received PCV13 (n=25)	Received PCV13 (n=97)
Toddler dose analysis	Included in EIP (n=21) Excluded from EIP* (n=4)  • Visit outside age range (n=1)  • Blood draw out of window (n=2)  • No assay result before and after toddler dose (n=1)  • Did not receiv e 4 doses of PCV13 (subject withdrawn; n=1)	Included in EIP (n=46) Excluded from EIP* (n=4) •Visit outside age range (n=3) •Toddler dose blood draw out of window (n=1) •No assay result before and after toddler dose (n=1)	Included in EIP (n=21) Excluded from EIP* (n=4) •Visit outside age range	Included in EIP (n=88) Excluded from EIP* (n=12) •Visit outside age range (n=7) •No assay result before and after toddler dose (n=3) •Did not receive 4 doses of PCV13 (subject withdrawn; n=3) •Toddler dose blood draw out of window (n=2)
	No assay result after toddler dose (n=1)			
1-voar	Completed (n=20) Withdrawn after toddler dose (n=4) •No longer willing to participate in study (n=3) •Lost to follow-up (n=1)	Completed (n=46) Withdrawn after toddler dose (n=4) •No longer willing to participate in study (n=1) •Lost to follow-up (n=3)	Completed (n=22) Withdrawn after toddler dose (n=3) •No longer willing to participate in study (n=3)	Completed (n=88) Withdrawn after toddler dose (n=9) •No longer willing to participate in study (n=9)
	Included in EIP (n= 19) Excluded from EIP* (n=6) •Visit outside age range (n=1) •No assay result after 1-year follow-up (n=5)	Included in EIP (n= 43) Excluded from EIP* (n=7) •Visit outside age range	Included in EIP (n= 18) Excluded from EIP* (n=7) • Visit outside age range	Included in EIP (n=80) Excluded from EIP* (n=20) •Visit outside age range (n=7) •No assay result after toddler dose (n=13)
2-vear	Completed (n=19) Withdrawn after toddler dose (n=4) •No longer willing to participate in study (n=3) •Lost to follow-up (n=1)	Completed (n=40) Withdrawn after toddler dose (n=6) •No longer willing to participate in study (n=5) •No longer eligible (n=1)	Completed (n=22)	Completed (n=80) Withdrawn before 2-year follow-up after toddler dose (n=8)  •No longer willing to participate in study (n=6)  •No longer eligible (n=2)
	Included in EIP (n= 18) Excluded from EIP* (n=7) • Visit outside age range	Included in EIP (n= 36) Excluded from EIP* (n=14)  •Visit outside age range	Included in EIP (n= 17) Excluded from EIP* (n=8)  • Visit outside age range	Included in EIP (n=71) Excluded from EIP* (n=29) •Visit outside age range (n=7) •No assay results after toddler dose (n=20) •Blood draw out of window (n=2)

doses of PCV13 at 2, 3, and 4 months of age; toddler dose=1 dose of PCV13 at 12 months of age; EIP=evaluable immunogenicity population; GA=gestational age.\*Subjects could have been excluded for more than one reason.